Graphite Bio Revenue and Competitors
Estimated Revenue & Valuation
- Graphite Bio's estimated annual revenue is currently $4.9M per year.
- Graphite Bio's estimated revenue per employee is $77,500
- Graphite Bio's total funding is $195.7M.
Employee Data
- Graphite Bio has 63 Employees.
- Graphite Bio grew their employee count by -53% last year.
Graphite Bio's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Head Talent Strategy and Executive Search | Reveal Email/Phone |
4 | Head People Programs & Business Partnerships | Reveal Email/Phone |
5 | SVP Development | Reveal Email/Phone |
6 | Director, Supply Chain | Reveal Email/Phone |
7 | Associate Director, People Operations & Total Rewards | Reveal Email/Phone |
8 | Director, Clinical Data Management | Reveal Email/Phone |
9 | Chief Strategy Officer (CSO) | Reveal Email/Phone |
10 | Senior Director Software Engineering | Reveal Email/Phone |
Graphite Bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $110.3M | 709 | -9% | N/A | N/A |
What Is Graphite Bio?
Graphite Bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. The company's platform harnesses the natural cellular process of homology directed repair (HDR) and targeted DNA integration to precisely repair genetic defects at their source. Graphite Bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients' lives
keywords:N/A$195.7M
Total Funding
63
Number of Employees
$4.9M
Revenue (est)
-53%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Graphite Bio News
Should You Accumulate Graphite Bio Inc (GRPH) Stock Monday Morning? Monday, April 18, 2022 07:24 AM | InvestorsObserver Analysts. Should You Accumulate...
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new...
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new...
Graphite Bio’s technology precisely finds and replaces genes, offering potential cures for genetic diseases. The gene-editing biotech is preparing to bring its most advanced therapeutic candidate into human testing later this year and its IPO raised $238 million for that program and others in it ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.2M | 63 | N/A | N/A |
#2 | $26.8M | 63 | 13% | $130M |
#3 | $12M | 65 | -10% | N/A |
#4 | N/A | 65 | 141% | N/A |
#5 | $8.3M | 66 | -3% | $80.9M |